Shanghai Shenlian Biomedical Co., Ltd. (hereinafter referred to as "Shenlian Bio") was established in June 2001 with a registered capital of 409.7 million RMB. Shenlian Bio is a high-tech enterprise specializing in the research and development, production and sales of veterinary biological products. In October 2019, Shenlian Bio went public on the Science and Technology Innovation Board of Shanghai Stock Exchange with the stock code of 688098.
Shenlian Bio is a designated foot-and-mouth disease (hereinafter referred to as "FMD") vaccine manufacturer by the Ministry of Agriculture and Rural Affairs of the PRC. Shenlian Bio's development and production of FMD synthetic peptide vaccine has been the first in the world, which also made important contributions to the prevention and control of FMD in China. Shenlian Bio has three GMP manufacturing bases, which are Shanghai veterinary diagnostic products workshop and Lanzhou synthetic peptide vaccine workshop and cell suspension culture inactivated vaccine workshop. Lanzhou branch has taken the lead in passing the National Major Animal Disease Bio-safety Level 3 protection acceptance.
Shenlian Bio is a national high-tech enterprise and Shanghai enterprise technology center. It has been awarded the honor of Shanghai Patent Pilot Enterprise, Shanghai Top 10 High-Tech Independent Innovation Enterprise, Shanghai Specialized and Special New Enterprise, Shanghai Minhang Top 100 Enterprise, etc.
Shenlian Bio has a research and development team with technical consultant ZHANG Gaiping, academician of the Chinese Academy of Engineering, and other senior experts, foreign experts and overseas returnee scientific leaders as the main force of scientific research. It has formed a multi-dimensional and multi-level technology platform based technology on synthetic peptide vaccine, inactivated vaccine and virus like particle vaccine, and has established a good Industry-University-Research Collaboration with well-known domestic and overseas' Scientific Research Academy.
Since its establishment, Shenlian Bio has obtained a number of national science and technology awards, including the second prize of National Science and Technology Progress Award, Global Science and Technology Innovation Award, and National Class I New Veterinary Drug Certificate, etc. It has 6 national new veterinary drug certificates, 24 invention patents and 46 utility model patents.
Quality builds the brand, and all-around quality management is the cornerstone of enterprise management. In accordance with the international quality management systems such as EU GMP and US FDA, we have established a scientific and efficient three-level quality management system by adopting GMP and ISO double system certification, and actively build an international level quality management system. Through strict control of R & D quality, material procurement, production process, product release and after-sales service, 100% qualified rate of products and 100% qualified rate of supervision and sampling inspection were achieved.
Shenlian Bio has established over 30 provincial service centers and 28 cooperative service institutions, its marketing and service network covers 31 provinces and cities in China. Shenlian Bio has been maintaining the first position in the FMD synthetic peptide vaccine market, ranking the third in the domestic pig biological products market, and the product brand is widely recognized.
Shenlian Bio is committed to building a world-class high-tech biological company. With the mission of "Pioneering Life Science and Technology and Creating Great Cause of Human Health", Shenlian Bio adheres to the concept of "Innovation Leading Development, Quality Casting Brand, Honest Service for Customers, and Gathering Talents to Build the Future", so as to provide better products and services for China's animal disease prevention and control.